2
项与 Adenovirus-transfected DCs+ CIK(Affiliated Hospital to Academy of Military Medical Sciences) 相关的临床试验 / Unknown status临床1/2期IIT Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ/Ⅱ Study
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
100 项与 Adenovirus-transfected DCs+ CIK(Affiliated Hospital to Academy of Military Medical Sciences) 相关的临床结果
100 项与 Adenovirus-transfected DCs+ CIK(Affiliated Hospital to Academy of Military Medical Sciences) 相关的转化医学
100 项与 Adenovirus-transfected DCs+ CIK(Affiliated Hospital to Academy of Military Medical Sciences) 相关的专利（医药）
100 项与 Adenovirus-transfected DCs+ CIK(Affiliated Hospital to Academy of Military Medical Sciences) 相关的药物交易
